The product affected by this notice is sold under the trade name TomoTherapy SharePlan 1.1. To determine if the version you are using is affected, bring up the About box in the SharePlan application and check if the build number reported there is 1.3.1.10. Intended use: t-RayAutoplan is a software that, based on the planned dose distribution from a TomoPlan treatment planning system, generates a family of individually optimized IMRT plans and presents their characteristics to the user in a GUI. Among the generated plans, the user selects and clinically approves a treatment plan and exports it electronically to DICOM, for subsequent treatment of the patient. The intended users of t-RayAutoplan shall be clinically qualified staff, such as medical physicists, medical doctors or dosimetrists
Published September 26, 2012 · Recall initiated: May 30, 2011
Summary
FDA records medical device Class II recall Z-2378-2012, published September 26, 2012 and initiated May 30, 2011. Recalling firm: RAYSEARCH LABORATORIES AB; Status: Terminated; Reported quantity: 15 units; Lot: SharePlan 1.1, aka t-RayAutoplan version 1.2.1 (build number 1.3.1.10). Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
This field notice concerns two behaviors of the SharePlan (Multiple Fraction Groups and Depth Offset) that may be unexpected and are not clearly described in the user manual. None of these behaviors have caused patient mistreatment or other incidents. However, the described user actions must be adhered to for best agreement between treatment plan evaluation and the clinical outcome of the delivere
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- RAYSEARCH LABORATORIES AB
- Distributor
- Worldwide Distribution - USA including CA, KY, MI, NY, OK, and OR. Internationally to Canada, Belgium, United Kingdom, Australia, France, Germany, and Poland.
- Lot
- SharePlan 1.1, aka t-RayAutoplan version 1.2.1 (build number 1.3.1.10).
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- Sweden
Related recalls
- FDARayCare 2024A SP4. Oncology Information Systems.July 8, 2026
- FDARayCare 2024A SP1. Oncology Information Systems.July 8, 2026
- FDABrand Name: RayStation Product Name: RayStation/RayPlan Model/Catalog Number: 14.0.0, 15.0.0, 15.1.3 SoftwareJanuary 28, 2026
- FDABrand Name: RayStation Product Name: RayStation/RayPlan Model/Catalog Number: 17.0.0, 17.0.1 Software Version:January 28, 2026
- FDABR980-9600 Hysteroscopy Sterile Procedure Kit containing 2 oz. bottle PVP Prep Solution Product Usage: Usage:September 26, 2012
- FDAHALO Flex Energy Generators Manufactured by B®RRX Medical (now Covidien) 540 Oakmead Parkway Sunnyvale, CASeptember 26, 2012
Questions about this recall
Was The product affected by this notice is sold under the trade name TomoTherapy SharePlan 1.1. To determine if the version you are using is affected, bring up the About box in the SharePlan application and check if the build number reported there is 1.3.1.10. Intended use: t-RayAutoplan is a software that, based on the planned dose distribution from a TomoPlan treatment planning system, generates a family of individually optimized IMRT plans and presents their characteristics to the user in a GUI. Among the generated plans, the user selects and clinically approves a treatment plan and exports it electronically to DICOM, for subsequent treatment of the patient. The intended users of t-RayAutoplan shall be clinically qualified staff, such as medical physicists, medical doctors or dosimetrists recalled?
Yes. FDA published recall Z-2378-2012 on September 26, 2012. Reported hazard: This field notice concerns two behaviors of the SharePlan (Multiple Fraction Groups and Depth Offset) that may be unexpected and are not clearly described in the user manual. None of these behaviors have caused patient mistreatment or other incidents. However, the described user actions must be adhered to for best agreement between treatment plan evaluation and the clinical outcome of the delivere
What should I do if I have this product?
Voluntary: Firm initiated · Letter